A Year Later, 11-year-old Shows No Symptoms of Type 1 Diabetes

Published date: |
Estimated read time: |
Authored by:
  • AdventHealth
Topics:
Our Communities Our Team and Culture Science and Innovation
Anderson Ata and his family collage

It has been a little over a year since Anderson Ata, a typical 11-year-old who likes playing basketball and hanging out with his friends, got really sick.

During the night of New Year’s Eve 2022, Anderson said, “I took a couple of covers from my cabinet and put them on me, waited an hour and I was still shaking, and I didn’t know what was happening.” Anderson shared his story with FOX 35 news.

After an ER visit last January, Anderson learned he had the early stages of Type 1 diabetes. The family made an appointment with Konda Reddy, MD, medical director of pediatric endocrinology and diabetes at AdventHealth for Children, to explore possible treatment with a brand-new FDA-approved drug called TZIELD.

TZIELD is the first drug that has been shown to delay the progression of Type 1 diabetes by up to three years in adults and up to eight years in children. Anderson became the seventh patient in the world, and the first in Florida to receive the life-changing treatment.

Just recently, Anderson and his parents, Joe and Jill Ata, shared with WMFE the good news that, a year later, Anderson shows no symptoms.

AdventHealth was part of the large global research study that led to the FDA’s approval of TZIELD. Because of its participation, AdventHealth’s Central Florida Division, along with a handful of other hospital systems, was among the first in the world to administer TZIELD, which is a 14-day intravenous treatment, when it became available at the beginning of 2023.

Recent News

Media Coverage
Health care CEO rethinks transaction strategy after Hurricane Helene

St. Luke's Hospital in Columbus, North Carolina, had been planning to ink a management agreement with AdventHealth, one of the nation's largest health systems, for months. But just days before the...

Read the full story on Newsweek
View More Articles